Silencing of CXCR2 and CXCR7 associates with progression. A and B. IHC of CXCR2 in normal tissue and cancer tissue, respectively; C and D. IHC of CXCR7 in normal tissue and cancer tissue, respectively; E. Quantitative analysis of IHC; F and G. Expression of CXCR2 and CXCR7 in EC tissues correlates with a lower cancer patient survival rate, respectively. IHC, immunohistochemistry; CXCR, chemotaxis cytokine receptor; ESCC, esophageal squamous cell carcinoma.